Overview
- The 51-year-old says months of progressive blur are affecting his ability to see faces at shows and even players at a football game.
- He reports a changed prescription and new glasses, and says he suspects the injections rather than age are responsible.
- He plans to continue treatment despite the concern, joking he would stay on it even if vision in one eye were lost.
- Coverage references a recent U.S. observational study reporting an association between GLP-1 drugs and NAION, and nearly 300 UK reports of eye disorders allegedly linked to Mounjaro.
- Manufacturer Eli Lilly says patient safety is a priority and it is reviewing ophthalmic data in ongoing talks with regulators, and no causal link has been established.